Long-term use of DPP-4 inhibitors raises some concerns regarding their effects on the pancreas and cardiovascular health. Continuous monitoring through clinical trials and post-marketing surveillance is essential to assess these risks. Patients should be advised to report any unusual symptoms promptly.
